Omeros Drug Test Shows Postoperative Benefits

Seattle-based pharmaceutical company Omeros announced positive results from its final Phase 3 clinical trial of OMS302, a drug added to irrigation solutions after cataract or lens replacement surgery.

Advertisement

 

In November, Omeros announced the results from the clinical trial showed the drug met co-primary efficacy endpoints with better pupil dilation and pain reduction after surgery.

 

More Articles on Ophthalmology:

56 Physician-Owned Hospitals to Know
20 Physicians Scattered Throughout 113th Congress
Ophthalmologist on the Move: Dr. Augustus Stern Joins MD’s Bergman Eye Center

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.